CS Paper Radar

CFB-GBM v2.0: An Augmented Longitudinal Dataset for Multi-Modal Glioblastoma Segmentation, Radiomics, and RANO Progression Tracking

Alexandre G. Leclercq, Noémie N. Moreau, Hugo Audebert, Andros Nassar, Thomas Cochin, Thomas Leleu, Loïc Le Henaff, Alexis Desmonts, Yoann Poirier, Aurélie Dubru, Laura Guillemette, Pascal Lecoeur, Kévin Lemasson, Cyril Jaudet, Sébastien Bougleux, Romain Hérault, Carole Brunaud, Samuel Valable, Dinu Stefan, Charlotte Raboutet, Alain Batalla, Joëlle Lacroix, Roman Rouzier, Aurélien Corroyer-Dulmont

cs.CV ·submitted 2026-08-18 15:18 UTC · v1
top venue

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of 15 months. Longitudinal, multi-modal imaging datasets with comprehensive clinical and treatment data are essential to support the development of reproducible computational methods for treatment response prediction, disease progression modelling, and personalized medicine. We present CFB-GBM v2.0, an extension of our previously released CFB-GBM dataset comprising 264 GBM patients treated according to the standard Stupp protocol. The primary contribution of this release is the completion of Gross Tumour Volume (GTV) delineations across all available timepoints ($t_0$, $t_1$ and $t_2$), increasing the overall GTV completion rate from 35% to 97%. This was achieved using a nnU-Net model pre-trained on BraTS 2021 and fine-tuned on CFB-GBM ground-truth contours, with the generated segmentations validated by five radiation oncologists. From these longitudinal GTV annotations, volumetric RANO 2.0 response category labels were derived for all available temporality pairs ($t_0 \rightarrow t_1$, $t_0 \rightarrow t_2$ and $t_1 \rightarrow t_2$). To further ease dataset usability and reproducibility, brain masks computed with HD-BET and pre-computed radiomic features extracted with PyRadiomics are provided for each patient timepoint and MRI modality. Additionally, the WHO classification guideline (2016 vs. 2021) applicable to each patient's diagnosis is now explicitly documented. CFB-GBM v2.0 is publicly available on The Cancer Imaging Archive (TCIA) at https://www.cancerimagingarchive.net/collection/cfb-gbm .

Comment
9 pages, 2 figures,
DOI
10.59275/j.melba.2026-dd48

Closest papers

Nearest neighbours by meaning across the whole index.

A Simple yet Effective Framework for Pre-treatment and Post-treatment Glioma Segmentation Using Multimodal MRI

eess.IV ·2026-10-01 ·Lin Qu, Ziqi Chen, Anqi Wu, Jinyao Shen, Hai Shu
published similarity 0.73
Abstract · The proposed method won second place in the MICCAI 2025 BraTS Lighthouse Challenge on Glioma Segmentation on Pre- and Post-Treatment MRI (Br…

Accurate glioma segmentation across pre- and post-treatment MRI remains challenging because treatment alters both image appearance and the target regions. In particular, the resection cavity (RC) is defined only for post-treatment cases, complicating joint learning from pooled data. We present RC-aware nnU-Netv2, a simple yet effective glioma segmentation framework that combines lesion- and boundary-aware single-cohort training, an RC-aware joint learning objective, and treatment-status-guided model routing at inference. During pooled training, the joint objective applies both standard and boundary-weighted binary cross-entropy to all four region channels, while employing Dice supervision for channels with non-empty targets and a controlled false-positive penalty for channels with empty targets across the mini-batch. This design explicitly accommodates the absence of RC in pre-treatment cases. Our approach uses only the standard nnU-Netv2 data augmentation and a single specialized model per case, without additional synthetic tumor generation or multi-model ensembling. RC-aware nnU-Netv2 ranked second in the BraTS 2025 Lighthouse Challenge Task 1 (BraTS-GLI 2025), with segmentation performance comparable to that of the first-place method, which relied on on-the-fly GliGAN-based synthetic tumor augmentation and multi-model ensembling. On the official blind test set, our method achieved mean lesion-wise Dice scores of 0.7878, 0.8709, 0.7923, and 0.8715 and mean NSD@1.0 scores of 0.8309, 0.8712, 0.7980, and 0.8336 for enhancing tumor, RC, tumor core, and whole tumor, respectively. In paired post-treatment analysis, the RC-aware joint model improved mean lesion-wise Dice by 0.042 (95% CI: [0.028, 0.057]) and mean NSD@1.0 by 0.043 (95% CI: [0.028, 0.059]) compared with the joint baseline.

0.13

GliomaINK: A Tumor and Anatomy Conditioned Flow Matching Framework for 3D MRI Sequence Synthesis in Glioma Patients

eess.IV cs.CVq-bio.TO ·2026-10-16 ·Moinak Bhattacharya, Annie Singh, Mohammad Chaudhry, Prateek Prasanna, Gagandeep Singh
similarity 0.69
Abstract

Background: Incomplete multiparametric MR examinations limit glioma characterization and downstream AI tools. Generative models can synthesize missing MRI sequences, but anatomical structure and clinically relevant tumor features are challenging to preserve. We propose GliomaINK, an anatomy-guided conditional flow matching framework for cross-sequence 3D brain MRI synthesis. Methods: A 3D SwinUNETR predicted the conditional velocity field while an auxiliary topology-preserving loss encouraged structural consistency. The model was trained on 1,083 patients from the BraTS-AG dataset and independently tested on an in-house clinical cohort. Downstream tasks include image quality, tumor segmentation, IDH1 mutation-status prediction, and overall survival prediction. Two radiologists independently evaluated the anatomical fidelity, pathological representation, and overall image quality of the synthesized images. Results: GliomaINK exhibited the highest PSNR across all six MRI translation directions in both evaluation cohorts. In the BraTS-AG test set, the PSNR reached $25.64\pm0.55$ dB for the T2W-to-T1C synthesis, compared with $13.78\pm0.32$ dB for Pix2Pix and $18.90\pm0.53$ dB for SPADE. For downstream tumor segmentation, the method showed strong performance across tumor subregions with Dice scores reaching $0.928\pm0.014$ for edema, and $0.885\pm0.040$ for enhancing tumor. For the IDH1 mutation-status prediction, GliomaINK achieved the highest AUROC score in four of the six sequence configurations, reaching $0.827\pm0.088$. Conclusion: Anatomy-guided conditional flow matching enables high-fidelity cross-sequence glioma MRI synthesis demonstrating potential for preservation of clinically relevant information in synthesized MRI and improving downstream tasks.

0.18

VGG16-MCA UNet: Whole-Tumor Segmentation in 2D FLAIR MRI with Decoder-Side Channel Attention

eess.IV cs.CV ·2026-09-20 ·Shubham Gajjar, Deep Joshi, Avi Poptani, Vishal Barot
benchmarktheorycode/data similarity 0.66
Abstract · 22 pages, 7 figures, 4 tables. Code and data splits: https://github.com/ShubhamGajjar/vgg16-mca-unet

Automated brain tumor segmentation supports diagnosis, treatment planning, and monitoring of disease progression, but building models that generalize across heterogeneous tumors and limited annotated data remains difficult. We present VGG16-MCA UNet, a hybrid architecture pairing an ImageNet-pretrained VGG16 encoder with a decoder in which a Multi-Channel Attention (MCA) module recalibrates features after each skip-connection fusion, trained with the Focal Tversky loss to counter severe foreground-background imbalance. We evaluate the model as a 2D, FLAIR-only, whole-tumor segmenter on tumor-positive slices from two public datasets: the BraTS 2020 benchmark and the LGG MRI Segmentation dataset. Using 5-fold cross-validation and a single network formed by averaging the weights of the five fold models, the method attains an aggregate pixel-level Dice (F1) of 95.10% on our held-out BraTS 2020 split and 88.32% on LGG. These scores are computed over all test pixels pooled into a single confusion matrix rather than averaged per case, and are therefore not directly comparable to the per-case mean Dice used in the BraTS challenge protocol. All partitions were drawn over individual slices rather than over patients, so every patient contributes slices to both training and test; the figures above therefore measure interpolation within known patients and should be read as an upper bound rather than as generalization to new ones. The model segments a 256x256 slice in 66.32 ms on a single 6 GB NVIDIA RTX 2060, approximately 8 ms more than an equivalent VGG16-UNet without MCA. We release the split records and report the protocol in full, with the aim of providing a precisely specified and reproducible 2D FLAIR baseline.

0.23

CAPS: Clinically-Verifiable Anatomy-Prioritized Synthesis for Missing MRI Imputation in Brain Tumor Segmentation

eess.IV cs.CV ·2026-10-20 ·Cecilia Diana-Albelda, Arthur Longuefosse, Mario Rubén Paz Campos, Álvaro García-Martín, Jesus Bescos
similarity 0.66
Abstract · 20 pages, 6 figures, 8 tables. Cecilia Diana-Albelda and Arthur Longuefosse contributed equally

Multi-parametric MRI is the gold standard for neuro-oncology, yet acquiring complete 4-modality protocols may be unfeasible in real-world clinical practice. When handling missing modalities, existing automated systems force a critical compromise: robust segmenters operate as uninterpretable "black boxes" that bypass image generation, while standard synthesis models often produce blurry reconstructions lacking diagnostic reliability. To address this issue, we propose CAPS, a Clinically-Verifiable Anatomy-Prioritized Synthesis framework that reconciles computational precision with clinical transparency. Our multi-modal generative architecture is driven by a hybrid objective function (L_1 + L_AFP + L_DualDice) that explicitly enforces the preservation of deep anatomical features and strict topological boundaries, rather than relying solely on pixel-wise optimization. Evaluated comprehensively on the BraTS Adult Glioma dataset, the framework achieves superior synthesis fidelity across intensity-based metrics, and demonstrates robust downstream segmentation performance (82.38% mean Dice), successfully restoring verifiable visual context. Furthermore, the framework exhibits exceptional zero-shot cross-domain generalization, maintaining high structural fidelity across completely unseen Meningioma, Pediatric, and Sub-Saharan African cohorts without domain-specific adaptation. Finally, a blinded radiological assessment confirms that our anatomy-aware approach significantly enhances both perceived image quality and clinical utility, providing clinicians with the reliable visual evidence required to trust downstream automated workflows.

0.20

Parameter-Efficient Multimodal Brain Tumor Segmentation With Stage-Wise Shared Adapters

cs.CV ·2026-10-13 ·Milad Rostamian, Mohammadreza Mohammadi, Ender Konukoglu, Mohsen Soryani
similarity 0.66
Abstract

Different MRI modalities reveal different parts of a brain tumor. Segmentation models combine information from these modalities to outline tumor regions. Many models use a separate encoder for each modality. However, exchanging features among these encoders at several stages can increase model complexity. We introduce the Block-Wise Shared Adapter (BWSA), which combines compressed features from the modality encoders in a shared path and returns adapted features to each stream. In its fixed-blending form, BWSA adds the adapted features to the original features. Its trainable-gated variant (TG-BWSA) instead learns separate weights for the original and adapted features at each modality and encoder stage. We evaluate both variants on BraTS 2020 and BraTS 2023 with four segmentation backbones. On the official BraTS 2023 online validation set, BWSA increases average region-wise Dice by 1.3--7.6 percentage points relative to the corresponding unmodified backbones. TG-BWSA increases it by 2.8--7.7 points. Both variants add approximately 0.85--3.73% parameters and reduce average HD95 relative to the unmodified backbones.

0.34

Pre- and Post-Treatment Brain Metastases Segmentation Using nnU-Net with Post-Processing for BraTS 2026

cs.CV ·2026-09-10 ·Haobin Liu, Xin Wang
publishedbenchmarkcode/data similarity 0.64
Abstract · Accepted to MICCAI 2026 Challenge BraTS-METS

Brain metastases exhibit high inter-lesion variability in size, enhancement pattern, and post-treatment appearance, making volumetric segmentation of both pre- and post-treatment cases the central challenge of the BraTS 2026 Task 1 (Brain Metastases). We build a pragmatic pipeline on a 5-fold nnU-Net ResEnc-L ensemble, in which each fold is trained independently for 1,000 epochs with the standard Dice + cross-entropy loss on 1,296 four-modality training cases. This ensemble is followed by a rule-based post-processing cascade tuned for the lesion-wise Dice similarity coefficient (LW-DSC), a detection-oriented metric that behaves very differently from the traditional global Dice. The final pipeline reaches an LW-DSC of 0.733 / 0.751 / 0.713 / 0.549 on the enhancing tumour (ET), tumour core (TC), whole tumour (WT), and resection cavity (RC) sub-regions on the official validation leaderboard. Rather than trusting these leaderboard gains, we audit every post-processing stage with a five-fold out-of-fold (OOF) analysis with no model-training leakage over all 1,296 training cases, scored with the official BraTS evaluation code (BraTS_evaluation): it confirms two stages as robust, per-fold-consistent improvements while the third improves only the leaderboard and does not reproduce out-of-fold. We further provide a mechanistic analysis of the LW-DSC metric that explains why recall-recovering post-processing carries low risk whereas component deletion does not, and we report thirteen negative results spanning loss engineering, alternative backbones, and inference-time settings, several of which run counter to widely held intuitions. Source code is released under Apache-2.0 at https://github.com/hornbeamliu/brats2026-met.

0.48

Evidence-Bound Reasoning: Neuro-Semantic Verification of Biomedical AI in Glioblastoma Radiogenomics

cs.CL ·2026-10-06 ·Mariya Miteva, Maria Nisheva-Pavlova
benchmark similarity 0.64
Abstract · 15 pages, 4 figures, 4 tables. Preprint

Background: Biomedical AI can generate plausible explanations without reliably verifying whether each statement is supported by patient-specific evidence. We developed a neuro-semantic verification framework that converts radiomic measurements into addressable evidence records and machine-checkable claims. Methods: UPenn-GBM radiomics were aligned with de novo CaPTk extraction from standardized MRI and expert-validated segmentations in an independent multicenter cohort. The shared space comprised 1,728 features from T1, T1GD, T2, and FLAIR MRI across three tumor regions. Reference-defined semantic states were derived from 611 UPenn cases. We evaluated cross-cohort transportability, model-linked provenance, deterministic verification, controlled predictive degradation, and an LLM claim-extraction pilot; MGMT prediction served only as a transport stress test. Results: Median semantic-state agreement was 0.786 (weighted kappa 0.709), ranging from 0.918 for morphologic to 0.252 for intensity features. The external evidence ledger contained 1,655 model-linked records for 331 patients. The verifier achieved 100% exact-set accuracy in a 6,620-claim corruption benchmark. In a 24-case pilot, GPT-5.6 Sol reproduced 72/72 prespecified atomic claims, and the frozen verifier recovered 24/24 expected conditions. During controlled degradation, ROC AUC declined from 0.899 to 0.500 while verification accuracy remained 1.000. External MGMT discrimination was weak (ROC AUC 0.543). Conclusions: Verifiability can be engineered and evaluated independently of predictive performance. LLMs may structure explanations, while final evidence-consistency checking remains deterministic.

0.23

Brain Metastases Segmentation for BraTS 2026 Task 1: A Multi-Architecture Comparison

cs.CV ·2026-09-21 ·Mahdi Islam, Musarrat Tabassum
publishedcode/data similarity 0.63
Abstract · 10 pages, 1 figure. Accepted as a poster at the BraTS 2026 Challenge, MICCAI 2026. Code: https://github.com/mahdiislam79/BraTS_METS_2026

Brain metastases are the most common intracranial malignancy, occurring in roughly 30% of patients with primary solid tumors and carrying a median survival near 5.9 months. Automated segmentation is critical for treatment planning and volumetric monitoring, but metastases are frequently small, numerous, and heterogeneous in size within a single patient. We compare a plain nnU-Net baseline, a Residual Encoder Large (ResEncL) variant, region-based training, and a Primus transformer model for BraTS-METS 2026 Task 1, using patient-grouped cross-validation to prevent leakage from the longitudinal UCSD subset. Primus (label-based) is our strongest individual model by aggregate DSC/NSD, achieving 0.710/0.761 (ET), 0.742/0.785 (TC), 0.683/0.689 (WT), and 0.531/0.436 (RC). ResEncL trails Primus on aggregate DSC/NSD but achieves substantially higher lesion-wise F1 (e.g. ET: 0.452 vs. 0.052); a probability-averaging ensemble of the two only partially preserves ResEncL's F1 advantage (ET lesion-wise F1: 0.064). We further report three postprocessing and label-reconstruction pitfalls we believe generalize beyond this challenge. Code is available at https://github.com/mahdiislam79/BraTS_METS_2026.

0.31